Cargando…

Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study

Preventing chemotherapy-induced thrombocytopenia could avoid chemotherapy dose reductions and delays. The safety and maximum tolerated dose of eltrombopag, an oral thrombopoietin receptor agonist, with gemcitabine-based therapy was evaluated. Patients with advanced solid tumors and platelets ≤300 × ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winer, Eric S, Safran, Howard, Karaszewska, Boguslawa, Richards, Donald A, Hartner, Lee, Forget, Frederic, Ramlau, Rodryg, Kumar, Kirushna, Mayer, Bhabita, Johnson, Brendan M, Messam, Conrad A, Mostafa Kamel, Yasser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312114/ https://www.ncbi.nlm.nih.gov/pubmed/25165041 http://dx.doi.org/10.1002/cam4.326

Ejemplares similares

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years
por: Rybarczyk-Kasiuchnicz, Agnieszka, et al.
Publicado: (2018)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Eltrombopag in Good's Syndrome
por: Kristiansen, Håvard Anton, et al.
Publicado: (2014)

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
por: Rybarczyk-Kasiuchnicz, Agnieszka, et al.
Publicado: (2021)

Preparation and Solid-State Characterization of Eltrombopag Crystal Phases
por: Abbinante, Vincenzo Mirco, et al.
Publicado: (2020)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
por: Stencel, Katarzyna, et al.
Publicado: (2021)

NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway
por: Zheng, Qiao, et al.
Publicado: (2020)

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
por: Erickson-Miller, Connie L, et al.
Publicado: (2012)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies
por: Wierzbicka, Małgorzata, et al.
Publicado: (2015)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

The Eltrombopag antitumor effect on hepatocellular carcinoma
por: KUROKAWA, TOMOHIRO, et al.
Publicado: (2015)

Multiple thrombosis during eltrombopag therapy
por: Shimazu, Yutaka, et al.
Publicado: (2021)

Exploring the Potential of Eltrombopag: Room for More?
por: Tarantini, Francesco, et al.
Publicado: (2022)

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines
por: Zhou, Jiarong, et al.
Publicado: (2019)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study
por: Ishii, Hiroshi, et al.
Publicado: (2018)

Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma
por: Li, Qiongxuan, et al.
Publicado: (2018)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Rice, Lawrence
Publicado: (2009)

Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016)

Eltrombopag in long‐term management of pediatric thrombocytopenia
por: Shah, Sanjay J., et al.
Publicado: (2018)

Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients
por: Dionisi, Marco, et al.
Publicado: (2021)

Adding eltrombopag to immunosuppression: the importance of predicting outcome
por: Tichelli, André, et al.
Publicado: (2022)

Eltrombopag directly activates BAK and induces apoptosis
por: Chen, Meng, et al.
Publicado: (2023)

Coffee Colored Serum, Adverse Reaction of Eltrombopag
por: Rojas, Carlos Rodríguez, et al.
Publicado: (2023)

Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
por: Luo, Wenhao, et al.
Publicado: (2019)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives
por: Sulewska, Anetta, et al.
Publicado: (2023)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
por: Hirsh, Vera, et al.
Publicado: (2007)

Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals
por: Kufel-Grabowska, Joanna, et al.
Publicado: (2022)

Encouraging long‐term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high‐risk patients with resectable pancreatic carcinoma
por: AlMasri, Samer S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_prmmreog9jso7cbbse1ht64jm0